{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:44Z","timestamp":1790709584695,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jid.2016.08.034","type":"journal-article","created":{"date-parts":[[2016,9,25]],"date-time":"2016-09-25T07:14:02Z","timestamp":1474787642000},"page":"313-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry"],"prefix":"10.1016","volume":"137","author":[{"given":"Paula","family":"D\u00e1vila-Seijo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Dauden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Descalzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vanaclocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco-Jos\u00e9","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"De la Cueva-Dobao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Herrera-Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Luis","family":"L\u00f3pez-Estebaranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merce","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Luis","family":"S\u00e1nchez-Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ferrandiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Jim\u00e9nez-Puya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-5260","authenticated-orcid":false,"given":"Ignacio","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"P\u00e9rez Zafrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mu\u00f1oz-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Mendiola-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"S\u00e1nchez Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ruiz-Genao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagrario","family":"Galiano Mej\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2016.08.034_bib1","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.3748\/wjg.v20.i43.16014","article-title":"Risk of infections associated with biological treatment in inflammatory bowel disease","volume":"20","author":"Andersen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jid.2016.08.034_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","article-title":"Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Armstrong","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2016.08.034_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2016.08.034_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jdv.12208","article-title":"Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry","volume":"28","author":"Carrascosa","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2016.08.034_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40257-014-0097-1","article-title":"Use of biologic agents in combination with other therapies for the treatment of psoriasis","volume":"15","author":"Cather","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib7","first-page":"504","article-title":"Prevalence of psoriasis in Spain in the age of biologics","volume":"105","author":"Ferrandiz","year":"2014","journal-title":"Actas dermosifiliogr"},{"key":"10.1016\/j.jid.2016.08.034_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jid.2016.08.034_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib10","article-title":"Should TNF-antagonists safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis Biobadaser and psoriasis Biobadaderm cohorts","author":"Garcia-Doval","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2016.08.034_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib14","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013Update 2015\u2013Short version\u2013EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2016.08.034_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib16","first-page":"300","article-title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up","volume":"11","author":"Reich","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jid.2016.08.034_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jid.2016.08.034_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2016.08.034_bib20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.12011","article-title":"Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry","volume":"27","author":"Sanchez-Moya","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2016.08.034_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib23","first-page":"3794","article-title":"[Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports]","volume":"102","author":"Soderlin","year":"2005","journal-title":"Lakartidningen"},{"key":"10.1016\/j.jid.2016.08.034_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1756-185X.2009.01393.x","article-title":"The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital","volume":"12","author":"Suwannalai","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jid.2016.08.034_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pauz.201100457","article-title":"[A new clinical disease entity. Tuberculosis in users of TNF-alpha inhibitors]","volume":"41","author":"Trautmann","year":"2012","journal-title":"Pharm Unserer Zeit"},{"key":"10.1016\/j.jid.2016.08.034_bib26","first-page":"34","article-title":"[Safety of anti-TNFalpha biological drugs]","volume":"57","author":"Trotta","year":"2005","journal-title":"Reumatismo"},{"key":"10.1016\/j.jid.2016.08.034_bib27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2016.08.034_bib28","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2016.08.034_bib29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","article-title":"Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy","volume":"167","author":"Wood","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jid.2016.08.034_bib30","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16324599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16324599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T21:12:55Z","timestamp":1749589975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X16324599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0022202X16324599"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2016.08.034","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2016.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}